ArticleClinical, cosmetic and investigational dermatology2025
Clinical Characteristics of Multiple Café-Au-Lait Macules and Their Potential Significance in the Early Screening of Genetic Diseases.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Café-au-lait macules in a cohort of Greek children genetically diagnosed with neurofibromatosis type 1: Prognostic significance beyond their diagnostic relevance.Dermatology online journal · 2026Article
- Clinical Characteristics, Dermoscopic Features and Prognosis of Acquired Facial Pigmented Macules in Young Children: A Retrospective Analysis of 160 Cases.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Café-au-lait macules (CALMs) are common skin manifestations, and their number and distribution may indicate potential genetic disorders, such as Neurofibromatosis Type 1 (NF1). This study aimed to investigate the clinical characteristics of multiple CALMs and their significance in the early screening of genetic disorders. Methods: This retrospective study included 98 patients diagnosed between May 2021 and May 2024 in two hospitals. Patients were divided into three groups based on the number of CALMs and whether other skin manifestations were present: Group 1 (≥ 6 CALMs with other skin manifestations), Group 2 (≥ 6 CALMs without other skin manifestations), and Group 3 (< 6 CALMs without other skin manifestations). Detailed clinical evaluations and imaging examinations were conducted to record the number, size, distribution of CALMs, and associated symptoms. Multivariate logistic regression analysis was performed to explore the relationship between CALMs and other systemic symptoms. Results: Group 1 patients showed significantly higher incidences of neurological symptoms (eg, neurofibromas 54%, P < 0.001) and skeletal system symptoms (eg, bone deformities 38%, P = 0.001) compared to Groups 2 and 3. Imaging examinations revealed an abnormality rate of 90% in Group 1 (P < 0.001). Logistic regression analysis indicated that the number of CALMs (≥ 10) was significantly associated with neurological (OR = 7.664, P = 0.001) and skeletal system symptoms (OR = 4.623, P = 0.014). The distribution of CALMs on the face and neck also showed a certain influence on symptoms. Conclusion: The number and distribution of CALMs are significant in the early screening of genetic diseases, particularly in identifying patients with potential neurological and skeletal system abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.